ASSET PURCHASE AGREEMENT by and between PROGENICS PHARMACEUTICALS, INC., as Seller, PERSPECTIVE THERAPEUTICS, INC., as Purchaser, AND For purposes of Section 9.12 only LANTHEUS MEDICAL IMAGING, INC. as Guarantor Dated as of January 8, 2024Asset Purchase Agreement • January 17th, 2024 • Perspective Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of January 8, 2024, is entered into by and between Perspective Therapeutics, Inc., a Delaware corporation (“Purchaser”) and Progenics Pharmaceuticals, Inc., a Delaware corporation (“Seller”) and, for purposes of Section 9.12 only, Lantheus Medical Imaging, Inc., Inc. a Delaware corporation (“Guarantor”). Purchaser and Seller are, from time to time, referred to individually herein as a “Party,” and collectively as the “Parties.”
OPTION AGREEMENTOption Agreement • January 17th, 2024 • Perspective Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
This Option Agreement (this “Agreement”) is dated as of January 8, 2024 (the “Effective Date”) by and between Lantheus Alpha Therapy, LLC, a Delaware limited liability company (“Lantheus”), and Perspective Therapeutics, Inc., a Delaware corporation (“Perspective”). Lantheus and Perspective may be referred to herein as a “Party” or, collectively, as “Parties”.
INVESTMENT AGREEMENTInvestment Agreement • January 17th, 2024 • Perspective Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
This Investment Agreement (this “Agreement”), dated as of January 8, 2024, by and between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business at 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121 and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (the “Investor”) with its principal place of business at 201 Burlington Road, South Building, Bedford, MA 01730. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.
